Soedarsono Soedarsono, Prinasetyo Kana Wulung Arie Ichida, Tanzilia Mayfanny, Nugraha Jusak
Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya, East Java, Indonesia.
Department of Clinical Pathology, Faculty of Medicine, Ciputra University, Surabaya, East Java, Indonesia.
Lung India. 2020 Mar-Apr;37(2):126-129. doi: 10.4103/lungindia.lungindia_395_19.
Tuberculosis (TB) continues to be a public health crisis with an estimated 10 million people developing TB disease in 2017. Adenosine deaminase (ADA) level in serum and pleural fluid as a biomarker may be used to diagnose pulmonary TB (PTB), but it is not always easy to obtain those samples at the end of treatment. This study was conducted to analyze the changes of serum ADA level in the new case of PTB patients with acid-fast bacilli (AFB) smear-positive sputum and sputum conversion status as treatment monitoring in PTB patients.
This was a prospective observational analytic study conducted in Dr. Soetomo General Hospital, Surabaya, from January 2018 to May 2018. Participants were all new cases of PTB patients with AFB smear-positive sputum, and a positive rapid molecular test for Mycobacterium tuberculosis. Blood serums were taken at the same time on the 1 day of TB treatment and also taken at the end of intensive phase treatment to analyze the changes of serum ADA level.
There were 26 TB patients and 26 healthy control people. Serum ADA level at the beginning of TB treatment was higher than the level at the end of intensive phase treatment. There was a significant difference between serum ADA level before and after the intensive phase of TB treatment (P < 0.001).
The examination of serum ADA levels can be used to evaluate the PTB treatment response.
结核病仍然是一场公共卫生危机，2017年估计有1000万人患上结核病。血清和胸腔积液中的腺苷脱氨酶（ADA）水平作为一种生物标志物可用于诊断肺结核（PTB），但在治疗结束时获取这些样本并非总是容易。本研究旨在分析痰涂片抗酸杆菌（AFB）阳性的新发PTB患者血清ADA水平的变化以及痰菌转阴情况，以此作为PTB患者治疗监测指标。
这是一项前瞻性观察性分析研究，于2018年1月至2018年5月在泗水苏托莫综合医院开展。研究对象为所有痰涂片AFB阳性且结核分枝杆菌快速分子检测呈阳性的新发PTB患者。在结核病治疗第1天同时采集血清，在强化期治疗结束时也采集血清，以分析血清ADA水平的变化。
共有26例结核病患者和26名健康对照者。结核病治疗开始时的血清ADA水平高于强化期治疗结束时的水平。结核病强化期治疗前后血清ADA水平存在显著差异（P < 0.001）。
血清ADA水平检测可用于评估PTB治疗反应。
